Mediso introduces nanoScan Family the next generation four modality preclinical imaging platform.

The first in vivo in-line multimodality imaging product family that offers ultimate SPECT, PET, CT and MRI performance in a unified imaging solution 

Dublin, Ireland – Sept. 5, 2012 – Mediso Medical Imaging Systems announced today at the World Molecular Imaging Congress (WMIC) the launch of the new nanoScan® next generation four modality preclinical imaging platform.

In recent years real multimodality imaging became an indispensable scientific need in the biomedical field. “The key challenge is to offer a complete portfolio covering all combinations of imaging modalities including SPECT, PET, CT and MRI.” says István Bagaméry, founder and CEO of Mediso. "With the two new members of the nanoScan® family, the SPECT/MRI and SPECT/CT, Mediso is the only company offering 4 different in-line imagers sharing the same platform. At the same time Mediso discontinues the production of two previous systems, the NanoSPECT/CT® and NanoPET®/CT and our production line is moved completely to the next generation of imaging systems.” However as a medical equipment manufacturer Mediso undertakes the full support of the formerly manufactured systems for more than 10 years via wide range of factory service plans and also offers various upgrade packages to the new nanoScan® platform.

The nanoScan® product line represents the latest technology in all imaging modalities. The new nanoScan® SPECT is based on the proprietary and patented* non-multiplexed M³-pinhole™ technology and delivers twice as high spatial resolution and sensitivity than the previously manufactured system. The nanoScan® PET, equipped with the new Tera-Tomo™ 3D reconstruction engine, performs quantitative PET studies combining high sensitivity with the unparalleled visible resolution of 700 microns. The high resolution CT and MRI images are not only applied for image co-registration and localization but also for CT-based or MRI-based attenuation and scatter correction for high resolution quantitative imaging. The seamless integration of the M2 MRI component from Aspect Imaging is ensured by its compact size and its zero fringe-field.

The design of the nanoScan® family was governed by the preclinical researchers’ needs. All imagers benefit from the development of the common hardware and software components resulting in a reliable and uniform performance and exceptional user experience.

The common components not only provide the scanners with uniform look and feel, but also ensure compactness, flexibility and full inter-compatibility:

All systems use a single, integrated framework for raw data acquisition, image reconstruction and archiving. Both SPECT and PET data are acquired and stored in list mode format for flexible and dynamic image processing. Quantitative imaging is supported by the proprietary and patented* Tera-Tomo™ 3D SPECT and PET multi-GPU based reconstruction algorithm with all corrections including CT and MRI based attenuation and scatter. The same MultiCell™ imaging chambers are available for all modalities ensuring temperature control and physiological monitoring of wide range of experimental animals.

The nanoScan® platform is an optimal solution for imaging and quantification in all major fields of preclinical biomedical research ranging through systems biology, signal transduction, cardiology, oncology and tumor biology, to development of multi-modal tracers and receptor studies in neuroscience.

Following the installation of the first nanoScan® PET/MRI at Karolinska Institute, Stockholm, Sweden in April, 2011, more than 10 systems are used today in various academic institutes including King’s College London, UK and Helmholtz-Zentrum Dresden-Rossendorf, Germany.

“nanoScan® combines anatomical and molecular imaging modalities using state-of-the-art PET technology with cutting edge resolution and sensitivity and unique user friendly MRI imaging for preclinical studies”, says Christer Halldin, Professor, Director of Karolinska Institute PET Center.

The nanoScan® in vivo molecular imaging platform is developed, manufactured and distributed by Mediso worldwide and can be seen at the World Molecular Imaging Congress (WMIC) in Dublin, Ireland in Mediso’s booth #217.

*Patents for the M3-pinhole™ and Tera-Tomo™ technologies are pending.

About Mediso Ltd.:

Mediso is one of the World's largest suppliers of various medical diagnostic and research purpose, single and multimodality imaging devices. The company was founded in 1990 by experts in the largest research and manufacturing company in Europe which has been engaged in nuclear equipment development and production since 1960.

Currently Mediso offers 4 imaging modalities - SPECT, PET, CT, MRI - for professionals working in laboratories and nuclear medicine departments.

Mediso products are sold worldwide directly and through a network of distributors. There are more than 1000 imaging systems operating in more than 85 countries around the world.

Mediso offers two multi-modality lines:

The current flagship of the preclinical line is the first member of the nanoScan® product family, the fully integrated in-line nanoScan® PET/MRI imager. With the introduction of two new members in 2012, the SPECT/MRI and the SPECT/CT, the nanoScan® family has quickly become a powerful, versatile four modality imaging platform.

Dominant member of the clinical line is the AnyScan® SPECT-CT-PET system, which is currently the only triple modality human diagnostic equipment and offers the most advanced SPECT detector technology, beside a full PET ring and a diagnostic CT.

Source: Mediso